Nearly 6,000 students across Malaysia have fallen ill with influenza-like symptoms, forcing authorities to close schools amid investigations into the outbreak's cause. Health officials are working to determine whether the widespread illness is linked to COVID-19 or another virus as they monitor the rapidly evolving situation. The scale of the outbreak has raised concerns about potential viral transmission within educational institutions, prompting swift containment measures. Authorities are conducting thorough investigations to identify the pathogen responsible for the symptoms affecting thousands of students nationwide. Officials emphasized close monitoring protocols to prevent further spread while schools remain shuttered. The incident highlights ongoing public health challenges as authorities balance educational continuity with student safety during viral outbreaks. (PC: X)

The Union Health Ministry has reminded parents and doctors that children under two years should not be given cough syrups, after 11 deaths were reported in Madhya Pradesh and Maharashtra. The fatalities, linked to Coldref and Nextro syrups, involved kidney failure and severe complications. While tests confirmed no contamination with diethylene glycol or ethylene glycol, the Directorate General of Health Services urged strict caution. Over 1,400 children are under medical observation for possible respiratory or renal issues. Officials stressed adherence to medical guidelines to avoid further tragedies nationwide. (PC: India Today)  

India’s drug regulator, CDSCO, has approved Ozempic (semaglutide), a once-weekly injectable by Danish firm Novo Nordisk, for managing Type 2 diabetes and aiding weight management. Novo Nordisk India MD Vikrant Shrotriya called it a “much-needed move” to modernize chronic disease care. Ozempic complements existing treatments like oral semaglutide and Wegovy for advanced obesity management. With semaglutide’s patent set to expire in March 2026, generic versions could enhance accessibility and affordability in India. Amid rising lifestyle-related illnesses, Ozempic’s launch is a key step toward expanding effective treatment options for diabetes and obesity patients nationwide.

A new report Children in India, 2025 reveals alarming rates of elevated triglycerides and LDL cholesterol among Indian kids. In the 5–9 age group, West Bengal leads with 67 % showing high triglycerides, followed by Sikkim (64.6 %) and Assam (57 %) . Among adolescents (10–19 years), 16 % exhibit high triglycerides; Bengal again tops at 42.5 % . These lipid imbalances damage blood vessels, foster early atherosclerosis, and raise long-term cardiovascular risk . Experts point to rising junk food consumption, sedentary lifestyle, and obesity. Prevention via diet, exercise, and regular screening is imperative. (PC: The Economic Times)

Kerala is on high alert after 19 people died from infections caused by the brain-eating amoeba this year. Health officials confirmed 72 infections, including 9 deaths in September alone. Last year, the state reported 36 infections and 9 deaths. The rare amoeba, called Naegleria fowleri, enters through the nose from contaminated water and destroys brain tissue. It does not spread from person to person. The fatality rate is above 95%, with symptoms like headache, fever, vomiting, seizures, and coma. Authorities are conducting large-scale testing across the state. Experts warn infections are rare but nearly always fatal. (PC: HT)

Kerala is grappling with a significant increase in cases of Primary Amoebic Meningoencephalitis (PAM), a rare and often fatal brain infection caused by the Naegleria fowleri amoeba. In 2025, the state has reported 67 confirmed cases and 19 deaths. The infection typically occurs when contaminated water enters the nasal passages, often during activities like swimming in warm freshwater bodies. Symptoms include severe headache, high fever, nausea, vomiting, and stiff neck. Health authorities have issued advisories urging the public to avoid swimming in untreated water and ensure proper chlorination of pools.   

Kerala has reported 19 deaths this year from Primary Amoebic Meningoencephalitis (PAM), a rare but deadly brain infection caused by the “brain-eating amoeba” Naegleria fowleri. Health officials confirmed 61 cases across the state, affecting people from infants to the elderly. The infection spreads when contaminated freshwater enters through the nose, often while swimming or bathing. It does not spread person-to-person. Symptoms include fever, headache, nausea, and vomiting, often mistaken for meningitis. The state government has urged people to avoid stagnant or untreated water, use nose clips when swimming, and clean wells and tanks properly. Early detection remains crucial for survival. (PC: NDTV)

Kerala has confirmed 67 cases of brain-eating amoeba infections this year, with 18 deaths, according to updated health data. A 17-year-old boy in Thiruvananthapuram was the latest case after visiting a swimming pool at Akkulam Tourist Village, which has now been closed. The deadly infection, caused by Naegleria fowleri, spreads when contaminated water enters the nose. Health Minister Veena George urged people to avoid stagnant or polluted water and ensure wells and swimming pools are chlorinated. She stressed, “The amoeba enters your brain through your nose.” The health department has stepped up surveillance and water safety measures across the state. (PC: India Today)

Kerala has confirmed 67 cases and 18 deaths from brain-eating amoeba this year, according to revised figures. A new case was reported in Thiruvananthapuram, where a 17-year-old boy tested positive after swimming at Akkulam Tourist Village. The health department has shut the pool and collected water samples. Health Minister Veena George urged strict safety steps, warning against bathing in stagnant or polluted water. She advised chlorination of wells, swimming pools, and clean home water storage. The amoeba enters through the nose, causing fatal brain infection. Two recent deaths were reported in Malappuram and Sulthan Bathery districts. (PC: India today )

Russia's Enteromix cancer vaccine has achieved 100% efficacy and safety in early clinical trials targeting colorectal cancer. Developed using mRNA technology similar to COVID-19 vaccines, the personalized immunotherapy is tailored to each patient's tumor profile. The trial involved 48 volunteers and was conducted by Russia's National Medical Research Radiological Centre with the Engelhardt Institute of Molecular Biology. Patients experienced tumor shrinkage without serious side effects. Announced at the 2025 St. Petersburg International Economic Forum, the vaccine awaits regulatory approval from Russia's Ministry of Health. Unlike conventional cancer vaccines, Enteromix offers fully personalized design and rapid mRNA platform adaptability, potentially transforming cancer treatment globally if validated through larger trials. (PC: X)